Skip to main content
Top
Published in: Digestive Diseases and Sciences 1/2011

01-01-2011 | Original Article

Intima-Media Thickness of the Common Carotid Artery Is Not Significantly Higher in Crohn’s Disease Patients Compared to Healthy Population

Authors: Efrat Broide, Andrei Schopan, Michael Zaretsky, Nimrod Alain Kimchi, Michael Shapiro, Eitan Scapa

Published in: Digestive Diseases and Sciences | Issue 1/2011

Login to get access

Abstract

Background

Patients with Crohn’s disease might have accelerated atherosclerosis due to: chronic systemic inflammation, metabolic changes or prolonged steroid treatment.

Aims

The aim of this study was to assess the risk of sub-clinical atherosclerosis in Crohn’s disease, by measuring the intima-media thickness and peak systolic velocity of the common carotid artery.

Methods

Fifty Crohn’s disease patients aged between 20 and 45 years were compared to 25 controls. Patients with a family history of cardiovascular diseases or a known risk for atherosclerosis were excluded. All participants underwent nutritional assessment. Carotid artery ultrasonography was performed and intima-media thickness and peak systolic velocity were measured, proximal to the common carotid bifurcation. Clinical data and laboratory parameters (hemoglobin, highly sensitive C-reactive protein, and plasma homocysteine) were determined.

Results

No significant differences between the groups were found for intima-media thickness or peak systolic velocity. Multiple regression analysis revealed a positive correlation of intima-media thickness with older age. Peak systolic velocity was negatively associated with age.

Conclusions

Crohn’s disease patients do not have an increased risk for developing early atherosclerosis.
Literature
1.
go back to reference Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation. 2003;108:1664–1672.CrossRefPubMed Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation. 2003;108:1664–1672.CrossRefPubMed
2.
go back to reference Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation. 2003;108:1772–1778.CrossRefPubMed Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation. 2003;108:1772–1778.CrossRefPubMed
3.
go back to reference Ripollés Piquer B, Nazih H, Bourreille A, et al. Altered lipid apolipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism. 2006;55:980–988.CrossRefPubMed Ripollés Piquer B, Nazih H, Bourreille A, et al. Altered lipid apolipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism. 2006;55:980–988.CrossRefPubMed
4.
go back to reference Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–1897.CrossRefPubMed Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–1897.CrossRefPubMed
5.
go back to reference Tilg H. Inflammatory bowel diseases: meeting of the European Crohn’s Colitis Organization, 1–3 March 2007, Innsbruck, Austria. Expert Opin Ther Targets. 2007;11:853–856.CrossRefPubMed Tilg H. Inflammatory bowel diseases: meeting of the European Crohn’s Colitis Organization, 1–3 March 2007, Innsbruck, Austria. Expert Opin Ther Targets. 2007;11:853–856.CrossRefPubMed
6.
go back to reference Fiocchi C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physio. 1997;273:G769–G775. Fiocchi C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physio. 1997;273:G769–G775.
7.
go back to reference Hatoum OA, Binion DG. The vasculature and inflammatory bowel disease. Contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis. 2005;11:304–313.CrossRefPubMed Hatoum OA, Binion DG. The vasculature and inflammatory bowel disease. Contribution to pathogenesis and clinical pathology. Inflamm Bowel Dis. 2005;11:304–313.CrossRefPubMed
8.
go back to reference Laroux FS, Grisham MB. Immunological basis of inflammatory bowel disease: role of the microcirculation. Microcirculation. 2001;8:283–301.PubMed Laroux FS, Grisham MB. Immunological basis of inflammatory bowel disease: role of the microcirculation. Microcirculation. 2001;8:283–301.PubMed
9.
go back to reference Talbot RW, Heppell J, Dozois PR, Beart RW Jr. Vascular complications of inflammatory bowel disease. Mayo Clin Proc. 1986;61:140–145.PubMed Talbot RW, Heppell J, Dozois PR, Beart RW Jr. Vascular complications of inflammatory bowel disease. Mayo Clin Proc. 1986;61:140–145.PubMed
10.
go back to reference Webbwerly MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut. 1993;34:247–251.CrossRef Webbwerly MJ, Hart MT, Melikian V. Thromboembolism in inflammatory bowel disease: role of platelets. Gut. 1993;34:247–251.CrossRef
11.
go back to reference Van-Doornum S, McColl G, Wicks IP. An extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 2002;46:862–873.CrossRefPubMed Van-Doornum S, McColl G, Wicks IP. An extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 2002;46:862–873.CrossRefPubMed
12.
go back to reference Sattar N, McCarey DW, Capell H, McInness IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108:2957–2963.CrossRefPubMed Sattar N, McCarey DW, Capell H, McInness IB. Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 2003;108:2957–2963.CrossRefPubMed
13.
go back to reference Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2399–2406.CrossRefPubMed Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003;349:2399–2406.CrossRefPubMed
14.
go back to reference Papa A, Danese S, Urgesi R, et al. Early atherosclerosis in patients with inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2006;10:7–11.PubMed Papa A, Danese S, Urgesi R, et al. Early atherosclerosis in patients with inflammatory bowel disease. Eur Rev Med Pharmacol Sci. 2006;10:7–11.PubMed
15.
go back to reference Maharshak N, Arbel Y, Bornstein NM, et al. Inflammatory bowel disease is not associated with increased intimal media thickening. Am J Gastroenterol. 2007;102:1050–1055.CrossRefPubMed Maharshak N, Arbel Y, Bornstein NM, et al. Inflammatory bowel disease is not associated with increased intimal media thickening. Am J Gastroenterol. 2007;102:1050–1055.CrossRefPubMed
16.
go back to reference Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gasteroenterol. 2007;102:662–667.CrossRef Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gasteroenterol. 2007;102:662–667.CrossRef
17.
go back to reference Papa A, Santoliquido A, Danese S, et al. Increased carotid intima–media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22:839–846.CrossRefPubMed Papa A, Santoliquido A, Danese S, et al. Increased carotid intima–media thickness in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005;22:839–846.CrossRefPubMed
18.
go back to reference Best WR. Predicting the Crohn’s disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis. 2006;12:304–310.CrossRefPubMed Best WR. Predicting the Crohn’s disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis. 2006;12:304–310.CrossRefPubMed
19.
go back to reference Friedewald WT, Levy RI, Friedrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMed Friedewald WT, Levy RI, Friedrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMed
20.
go back to reference Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the atherosclerosis risk in communities (ARIC) study. Am J Epidemiol. 1997;146:483–494.PubMed Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the atherosclerosis risk in communities (ARIC) study. Am J Epidemiol. 1997;146:483–494.PubMed
21.
go back to reference Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age. The muscattine study. Circulation. 2001;104:2815–2819.CrossRefPubMed Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age. The muscattine study. Circulation. 2001;104:2815–2819.CrossRefPubMed
22.
go back to reference Kumeda Y, Inaba M, Goto H, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46:1489–1497.CrossRefPubMed Kumeda Y, Inaba M, Goto H, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum. 2002;46:1489–1497.CrossRefPubMed
23.
go back to reference Durga J, Verhoef P, Bots ML, Schouten E. Homocysteine and carotid intima-media thickness: a critical appraisal of the evidence. Atherosclerosis. 2004;176:1–19.CrossRefPubMed Durga J, Verhoef P, Bots ML, Schouten E. Homocysteine and carotid intima-media thickness: a critical appraisal of the evidence. Atherosclerosis. 2004;176:1–19.CrossRefPubMed
24.
go back to reference Alkaabi JK, Ho M, Levison R, Pullar T, Belch JJ. Rheumatoid arthritis and macrovascular disease. Rheumatology. 2003;42:292–297.CrossRefPubMed Alkaabi JK, Ho M, Levison R, Pullar T, Belch JJ. Rheumatoid arthritis and macrovascular disease. Rheumatology. 2003;42:292–297.CrossRefPubMed
25.
go back to reference Park YB, Ahn CW, Choi HK, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum. 2002;46:1714–1719.CrossRefPubMed Park YB, Ahn CW, Choi HK, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum. 2002;46:1714–1719.CrossRefPubMed
26.
go back to reference Paoletti R, Gotto A, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation. 2004;109(Suppl III):III-20–III-26.CrossRef Paoletti R, Gotto A, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation. 2004;109(Suppl III):III-20–III-26.CrossRef
27.
go back to reference Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. The association of c-reactive protein, serum amyloid and fibrinogen with prevalent coronary heart disease–baseline findings of the PAIS project. Atherosclerosis. 2001;156:451–456.CrossRefPubMed Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. The association of c-reactive protein, serum amyloid and fibrinogen with prevalent coronary heart disease–baseline findings of the PAIS project. Atherosclerosis. 2001;156:451–456.CrossRefPubMed
28.
go back to reference Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol. 2000;6:619–623.CrossRef Grip O, Svensson PJ, Lindgren S. Inflammatory bowel disease promotes venous thrombosis earlier in life. Scand J Gastroenterol. 2000;6:619–623.CrossRef
29.
go back to reference Feigin VL, Anderseon CS, Mhurchu CN. Systemic inflammation, endothelial dysfunction, dietary fatty acids and micronutrients as risk factors for stroke: a selective review. Cerebrovasc Dis. 2002;113:219–224.CrossRef Feigin VL, Anderseon CS, Mhurchu CN. Systemic inflammation, endothelial dysfunction, dietary fatty acids and micronutrients as risk factors for stroke: a selective review. Cerebrovasc Dis. 2002;113:219–224.CrossRef
30.
go back to reference Oldenburg B, Fijnheer R, van der Griend R, vanBerge-Henegouwen GP, Koningsberger JC. Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol. 2000;95:2825–2830.CrossRefPubMed Oldenburg B, Fijnheer R, van der Griend R, vanBerge-Henegouwen GP, Koningsberger JC. Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol. 2000;95:2825–2830.CrossRefPubMed
31.
go back to reference Hudson M, Hutton RA, Wakefield AJ, Sawyerr AM, Pounder RE. Evidence for activation of coagulation in Crohn’s disease. Blood Coagul Fibrinolysis. 1992;3:773–778.CrossRefPubMed Hudson M, Hutton RA, Wakefield AJ, Sawyerr AM, Pounder RE. Evidence for activation of coagulation in Crohn’s disease. Blood Coagul Fibrinolysis. 1992;3:773–778.CrossRefPubMed
32.
go back to reference Souto JC, Martínez E, Roca M, et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci. 1995;40:1883–1889.CrossRefPubMed Souto JC, Martínez E, Roca M, et al. Prothrombotic state and signs of endothelial lesion in plasma of patients with inflammatory bowel disease. Dig Dis Sci. 1995;40:1883–1889.CrossRefPubMed
33.
go back to reference Younes-Mhenni S, Derex L, Berruyer M, et al. Large-artery stroke in a young patient with Crohn’s disease. Role of vitamin B6 deficiency-induced hyperhomocysteinemia. J Neurol Sci. 2004;221:113–115.CrossRefPubMed Younes-Mhenni S, Derex L, Berruyer M, et al. Large-artery stroke in a young patient with Crohn’s disease. Role of vitamin B6 deficiency-induced hyperhomocysteinemia. J Neurol Sci. 2004;221:113–115.CrossRefPubMed
34.
go back to reference Danese S, Sgambato A, Papa A, et al. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol. 2005;100:886–895.CrossRefPubMed Danese S, Sgambato A, Papa A, et al. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am J Gastroenterol. 2005;100:886–895.CrossRefPubMed
35.
go back to reference Stühlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocysteinemia: role of asymmetric dimethylarginine. Circulation. 2003;108:933–938.CrossRefPubMed Stühlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocysteinemia: role of asymmetric dimethylarginine. Circulation. 2003;108:933–938.CrossRefPubMed
36.
go back to reference Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost. 1999;81:165–176.PubMed Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost. 1999;81:165–176.PubMed
37.
go back to reference The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. JAMA. 2002;288:2015–2023.CrossRef The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. JAMA. 2002;288:2015–2023.CrossRef
38.
go back to reference Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenetrol Hepatol. 2008;6:41–45.CrossRef Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin Gastroenetrol Hepatol. 2008;6:41–45.CrossRef
39.
go back to reference Mutlu B, Ermeydan CM, Enc F, et al. Acute myocardial infarction in a young woman with severe ulcerative colitis. Int J Cardiol. 2002;83:183–185.CrossRefPubMed Mutlu B, Ermeydan CM, Enc F, et al. Acute myocardial infarction in a young woman with severe ulcerative colitis. Int J Cardiol. 2002;83:183–185.CrossRefPubMed
40.
go back to reference Sandrock M, Hansel J, Schulze J, et al. Sequentially based analysis versus image based analysis of intima media thickness in common carotid arteries studies—do major IMT studies underestimate the true relations for cardio- and cerebrovascular risk? Cardiovasc Ultrasound. 2008;6:32.CrossRefPubMed Sandrock M, Hansel J, Schulze J, et al. Sequentially based analysis versus image based analysis of intima media thickness in common carotid arteries studies—do major IMT studies underestimate the true relations for cardio- and cerebrovascular risk? Cardiovasc Ultrasound. 2008;6:32.CrossRefPubMed
41.
go back to reference Hrabovsky V, Zadák Z, Bláha V, Hypsler R, Karlík T. Changes in lipid metabolism in patients in the active phase of Crohn’s disease. Vnitr Lek. 2007;3:1035–1039. Hrabovsky V, Zadák Z, Bláha V, Hypsler R, Karlík T. Changes in lipid metabolism in patients in the active phase of Crohn’s disease. Vnitr Lek. 2007;3:1035–1039.
Metadata
Title
Intima-Media Thickness of the Common Carotid Artery Is Not Significantly Higher in Crohn’s Disease Patients Compared to Healthy Population
Authors
Efrat Broide
Andrei Schopan
Michael Zaretsky
Nimrod Alain Kimchi
Michael Shapiro
Eitan Scapa
Publication date
01-01-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1235-0

Other articles of this Issue 1/2011

Digestive Diseases and Sciences 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.